
Cellogen Therapeutics develops bispecific CAR-T cell therapies for cancer and blood disorders at lower cost than existing treatments.
$0Growth

Cellogen Therapeutics develops bispecific CAR-T cell therapies for cancer and blood disorders at lower cost than existing treatments.

Cellogen Therapeutics develops bispecific CAR-T cell therapies for cancer and blood disorders at lower cost than existing treatments.
Want a deeper look at Cellogen Therapeutics?
Ask Dormy who's likely on their cap table, what kind of companies their lead investor backs, and how to reach them.